Skip to main content
Trending
Corporate earningsAi infrastructureEnergy marketsElection litigationAviation safetyCrypto securityAi governanceEnterprise aiPlatform liabilityAvian influenzaClinical trialsFederal debtPresidential runoffRpg developmentSpace debrisAir defenseAutonomous vehiclesBudget crisisBug bountiesEnergy m&aForeign investmentFranchise restructuringGene therapyPandemic treatyTranslation pathwaysUn peacekeepingWeapons testingWeight-space programmingAi copyright lawArchaeological toxicology

full timeline

Combination Weight-Loss Drug CagriSema Achieves 23% Body Weight Reduction in Phase 3 Trial

Novo Nordisk's investigational drug CagriSema demonstrated superior weight loss compared to Eli Lilly's tirzepatide in a Phase 3 diabetes trial, while a separate study showed it drove 21% weight loss in adults with obesity.

Factlen Newsroom· Updated

Follow Combination Weight-Loss Drug CagriSema Achieves 23% Body Weight Reduction in Phase 3 Trial in the Factlen app and get an alert when there is news. Get the app

Novo Nordisk's investigational drug CagriSema combines semaglutide with the amylin analogue cagrilintide in a single weekly injection.From: Novo Nordisk's CagriSema Achieves 21% Weight Loss and Outperforms Tirzepatide in Phase 3 Trials

Share this story

Charts, maps and images

In the REIMAGINE 5 trial, patients with type 2 diabetes taking CagriSema achieved greater weight loss than those taking a 5.0 mg dose of tirzepatide.From: Novo Nordisk's CagriSema Achieves 21% Weight Loss and Outperforms Tirzepatide in Phase 3 Trials ·
Adults with overweight or obesity lost 21.0% of their body weight over 68 weeks on CagriSema, compared to 2.0% on placebo.From: Novo Nordisk's CagriSema Achieves 21% Weight Loss and Outperforms Tirzepatide in Phase 3 Trials ·
While CagriSema drove a massive 23% weight reduction, it narrowly missed the 25.5% mark set by tirzepatide in the REDEFINE 4 trial.From: Combination Weight-Loss Drug CagriSema Achieves 23% Body Weight Reduction in Phase 3 Trial ·
By targeting both GLP-1 and amylin receptors, CagriSema suppresses appetite through two distinct biological mechanisms.From: Combination Weight-Loss Drug CagriSema Achieves 23% Body Weight Reduction in Phase 3 Trial ·
CagriSema is currently under review by the FDA, with a regulatory decision expected in the fourth quarter of 2026.From: Novo Nordisk's CagriSema Achieves 21% Weight Loss and Outperforms Tirzepatide in Phase 3 Trials ·

Timeline

September 2026

  1. Novo Nordisk's CagriSema Achieves 21% Weight Loss and Outperforms Tirzepatide in Phase 3 Trials

August 2026

  1. Combination Weight-Loss Drug CagriSema Achieves 23% Body Weight Reduction in Phase 3 Trial